New Tris Ppromthazine With Codeine

Tris promethazine codeine is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older . This prescription medication is specifically reserved for adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. The product is not indicated for pediatric patients under 18 years of age due to the risks of serious adverse reactions, including life-threatening respiratory depression .

The recommended dosage for adults 18 years and older is 5 mL (one teaspoonful) every 4 to 6 hours as needed, not to exceed 6 doses (30 mL) in 24 hours . Healthcare providers should prescribe the medication for the shortest duration consistent with individual patient treatment goals, and patients with unresponsive cough should be reevaluated within 5 days or sooner for possible underlying pathology . Before refilling the prescription, providers must reevaluate the cause of the cough and assess the continued need for treatment, considering the relative incidence of adverse reactions and the potential for addiction, abuse, or misuse .

The product is contraindicated in several patient populations, including all children younger than 12 years of age, patients with significant respiratory depression, those with acute or severe bronchial asthma in an unmonitored setting, patients with known or suspected gastrointestinal obstruction, individuals with a history of idiosyncratic reaction to promethazine or other phenothiazines, and patients currently taking or who have taken monoamine oxidase inhibitors within the past 14 days